医薬品有効成分（API）市場規模、シェア、動向、2030年までの世界予測

医薬品有効成分（API）市場 – タイプ（革新的、ジェネリック）、合成（合成、バイオテクノロジー）、効力（HPAPI）、製品（mAbs、ホルモン）、医薬品（OTC、処方薬）、用途（糖尿病、腫瘍学）、競争環境 – 2030年までの世界予測

世界の医薬品有効成分（API）市場は、2025年の推定1,442億米ドルから2030年には1,983億9,000万米ドルに達し、2025年から2030年にかけて6.6%の年平均成長率（CAGR）で成長すると予測されています。原薬市場の拡大は、主に腫瘍・希少疾患領域および糖尿病領域の製品パイプラインの拡大によって牽引されてきました。ここ数年、2型糖尿病と肥満治療は、セマグルチド、チルゼパチド、リラグルチド、デュラグルチドといった新しいペプチド系薬剤の登場によって大きく様変わりしました。これらの治療法は、患者の転帰を変革し、APIサプライチェーン全体にわたって大きな機会を生み出しています。

この調査レポートでは、医薬品有効成分（API）市場をタイプ（革新的、ジェネリック）、効力（従来のAPI、高効力API（合成、生物製剤）、合成（合成、バイオテクノロジー）、製品（mAb、ホルモン、サイトカイン）発現システム）、薬物の種類（OTC、Rx）、治療用途（糖尿病、腫瘍学、CVD）、エンドユーザー（製薬およびバイオテクノロジー、CRO/CMO）、地域（北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東、アフリカ）別に分類しています。

本レポートは、医薬品有効成分（API）市場の成長に影響を与える主要な要因（促進要因、制約要因、課題、機会など）に関する詳細な情報を網羅しています。主要業界プレーヤーの詳細な分析により、事業概要、製品、ソリューション、主要戦略、提携、パートナーシップ、契約に関する洞察を提供しています。原薬市場に関連する新規承認／発売、提携、買収、最近の動向についても取り上げています。

本レポートは、医薬品有効成分（API）市場全体とそのサブセグメントの収益数値に最も近い近似値を提供することで、市場リーダー企業と新規参入企業を支援します。また、ステークホルダーが競争環境をより深く理解し、事業のポジショニングを改善し、適切な市場開拓戦略を策定するための洞察を深めるのに役立ちます。本レポートは、ステークホルダーが市場の動向を把握し、主要な市場牽引要因、制約要因、機会、課題に関する情報を提供することを可能にします。

Report Description

The global active pharmaceutical ingredients market is projected to reach USD 198.39 billion by 2030 from an estimated USD 144.20 billion in 2025, at a CAGR of 6.6% from 2025 to 2030. The expansion of the active pharmaceutical ingredients market has been predominantly fueled by the expanding oncology & rare disease and diabetes product pipeline. Over the past few years, type 2 diabetes and obesity care have been reshaped by a new class of peptide-based drugs, most notably Semaglutide, Tirzepatide, Liraglutide, and Dulaglutide. These therapies are transforming patient outcomes and creating significant opportunities across the API supply chain.

The pharmaceutical & biotechnology industry segment accounted for the largest share by end user in 2024.

Based on end users, the market is categorized into the pharmaceutical & biotechnology industry, contract research organizations (CROs), contract manufacturing organizations (CMOs), and other end users. The pharmaceutical & biotechnology industry accounted for the major end-user of active pharmaceutical ingredients (APIs), which are essential for drug development and manufacturing. The pharmaceutical industry has seen increasing manufacturing outsourcing to CMOs in the last 5 years, especially for developing and manufacturing drugs & biologics, such as high-potency drugs, ADCs, among others. However, pharmaceutical and biotechnology companies still dominate the end-user segment by retaining in-house manufacturing for high-value blockbuster drugs and biologics. Additionally, the rising demand for innovative therapies has encouraged continuous investment in research and development, with companies prioritizing the creation of novel drugs and advanced formulations. Together, these trends are expected to further strengthen the growth of the pharmaceutical and biotechnology end-user segment.

The innovative APIs segment accounted for the largest market share in the active pharmaceutical ingredients market by type.

Based on type, the global active pharmaceutical ingredients (API) market is divided into innovative APIs and generic APIs. In 2024, innovative APIs dominated the market, driven by the increasing number of regulatory approvals for new and advanced drugs, which is expected to continue supporting growth over the forecast period. For instance, the US FDA approved more than 50 new molecular entities (NMEs) in 2024, reflecting the rising pace of novel drug development. Innovative APIs, being protected by patents, are typically priced higher than generic APIs, contributing to their larger market share. The segment’s growth is further reinforced by the focus of pharmaceutical and biotechnology companies on developing novel therapies for complex and unmet medical needs, including oncology, rare diseases, and biologics. Additionally, investments in research and development, advanced manufacturing capabilities, and regulatory incentives continue to promote the introduction of innovative APIs. These factors position innovative APIs as the leading segment of the global API market, reflecting higher value and strong demand.

The Asia Pacific region is expected to grow at the highest CAGR in the global active pharmaceutical ingredients market during the forecast period.

The market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The Asia Pacific region is projected to grow at the highest CAGR during the forecast period. The key factors contributing to market growth include the increasing adoption and demand for high-value therapies, driving manufacturing expansion by global & regional players. In addition, the expansion of CDMOs in the region, which is focused on synthetic and biological therapies, is also helping drive demand for APIs. China, Japan, South Korea, India, and Australia are witnessing the growing adoption of innovative and generic medicine, which is supported by expanding manufacturing facilities in the Asia Pacific region. Furthermore, a combination of cost-efficient manufacturing, expanding generics and biosimilars production, and strong government support for local API manufacturing to reduce dependency on imports. India and China are emerging as global hubs owing to their large-scale production capacity, skilled workforce, and favorable regulatory initiatives, which support the growth of the active pharmaceutical ingredients market in the region.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side- 30%
• By Designation: Managers- 45%, CXOs and Directors- 30%, and Executives- 25%
• By Region: North America- 30%, Europe- 30%, Asia Pacific- 30%, Latin America- 5%, and the Middle East & Africa- 5%

Key Companies

Key players in the active pharmaceutical ingredients market include Pfizer (CentreOne) (US), Teva Pharmaceutical Industries Ltd. (Israel), Divi’s Laboratories Limited (India), Sandoz Group AG (Switzerland), SK Inc. (South Korea), Merck KGaA (Germany), Dr. Reddy’s Laboratories Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Cipla (India), Aurobindo Pharma (India), Evonik Industries AG (Germany), Hikma Pharmaceuticals plc (UK), BASF SE (Germany), Alembic Pharmaceuticals Limited (India), Siegfried Holding AG (Switzerland), EUROAPI (France), Asymchem (China), Bachem (Switzerland), Zhejiang Huahai Pharmaceutical Co., Ltd. (China), and Zhejiang Hisun (China).

Research Coverage

This research report categorizes the active pharmaceutical ingredients market, Active Pharmaceutical Ingredient Market by type (Innovative, generic), potency (traditional API, highly potent API (synthetic, biologics), synthesis ((synthetic, biotech), products (mAb, hormones, cytokines) expression system), type of drug (OTC, Rx), therapeutics application (diabetes, oncology, CVD), end user (pharma & biotech, CROs CMOs) and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the active pharmaceutical ingredients market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New approvals/launches, collaborations, acquisitions, and recent developments associated with the active pharmaceutical ingredients market.

Reasons to buy this report

The report will help market leaders and new entrants by providing them with the closest approximations of the revenue numbers for the overall active pharmaceutical ingredients market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (Surge in Demand for Complex APIs, Government Incentives & Supply Chain Reshoring, Adoption of Continuous Manufacturing & Digital Process Controls, Expanding Oncology & Rare Disease Pipeline Driving Outsourcing), restraints (Tightening regulatory requirements, high production costs in Western facilities and price pressure from generic tenders and single-winner procurement policies), opportunities (Critical medicines are commanding premium pricing through dual-sourcing and local manufacturing, China-Plus-One Strategy Boosting India, US, & EU Manufacturing Bases, and Integrated API-to-FDF CDMO Service Models Gaining Traction), and challenges (Supply Chain Concentration Risk, Quality Failures & Site Shutdowns Leading to Global Supply Disruptions, Capital-intensive Investments Needed for High-containment & Advanced Facilities and Geopolitical Tensions & Trade Restrictions Impacting API Flow)
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities in the active pharmaceutical ingredients market
• Market Development: Comprehensive information about lucrative markets across varied regions
• Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the active pharmaceutical ingredients market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the active pharmaceutical ingredients market.

Table of Contents

1               INTRODUCTION              49

1.1           STUDY OBJECTIVES       49

1.2           MARKET DEFINITION   49

1.3           INCLUSIONS AND EXCLUSIONS 50

1.4           STUDY SCOPE   50

1.4.1        SEGMENTS CONSIDERED             51

1.4.2        YEARS CONSIDERED      52

1.5           CURRENCY CONSIDERED            52

1.6           STAKEHOLDERS               52

1.7           SUMMARY OF CHANGES               53

2               RESEARCH METHODOLOGY       54

2.1           RESEARCH DATA              54

2.1.1        SECONDARY DATA          55

2.1.1.1    Objectives of secondary research       55

2.1.1.2    Key data from secondary sources       56

2.1.2        PRIMARY DATA 56

2.1.2.1    Breakdown of primaries (supply- and demand-side participants)                 57

2.1.2.2    Key objective of primary research      57

2.2           MARKET ESTIMATION  58

2.2.1        GLOBAL MARKET ESTIMATION 58

2.2.1.1    Company revenue analysis (Bottom-up approach)         58

2.2.1.1.1 Revenue share analysis of Pfizer, Inc.               59

2.2.1.2    MnM repository analysis     60

2.2.1.3    Primary interviews                60

2.2.2        INSIGHTS OF PRIMARY EXPERTS              61

2.2.3        SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)       61

2.3           GROWTH RATE PROJECTIONS  63

2.4           DATA TRIANGULATION                65

2.5           RESEARCH ASSUMPTIONS           66

2.6           RESEARCH LIMITATIONS             66

2.7           RISK ANALYSIS  67

3               EXECUTIVE SUMMARY  68

3.1           KEY INSIGHTS AND MARKET HIGHLIGHTS          68

3.2           ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: GLOBAL MARKET SIZE,

GROWTH RATE, AND FORECAST              68

3.3           STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS                 69

3.3.1        PHARMACEUTICAL CONTRACT MANUFACTURERS                 69

3.3.2        STARTUPS AND INNOVATIVE BIOTECH FIRMS  69

3.3.3        CDMOS/CROS   69

4               PREMIUM INSIGHTS       76

4.1           ACTIVE PHARMACEUTICAL INGREDIENTS MARKET OVERVIEW          76

4.2           NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY TYPE AND COUNTRY, 2025    77

4.3           ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS, BY TYPE      77

4.4           ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT            78

4.5           ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: GEOGRAPHIC

GROWTH OPPORTUNITIES         78

4.6           ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: EMERGING VS.

DEVELOPED MARKETS, 2025 VS. 2030      79

4.7           INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES              79

4.8           EMERGING BUSINESS MODELS AND ECOSYSTEM SHIFTS 80

4.9           VC/PRIVATE EQUITY INVESTMENT TRENDS AND STARTUP LANDSCAPE  80

4.10         REGULATORY POLICY INITIATIVES        81

5               MARKET OVERVIEW       82

5.1           INTRODUCTION              82

5.2           MARKET DYNAMICS       82

5.2.1        DRIVERS               84

5.2.1.1    Surge in demand for complex APIs   84

5.2.1.2    Favorable government incentives and supply chain reshoring                 84

5.2.1.3    Increasing adoption of continuous manufacturing and digital process controls    85

5.2.1.4    Rapid growth of oncology and rare disease pipelines     86

5.2.2        RESTRAINTS      88

5.2.2.1    Tightening regulatory requirements for nitrosamine and impurity controls  88

5.2.2.2    High production costs in US and Europe-based facilities                 89

5.2.2.3    Price pressure from generic tenders and single-winner procurement policies           89

5.2.3        OPPORTUNITIES              89

5.2.3.1    Growing emphasis on supply resilience and security of critical medicine manufacturing     89

5.2.3.2    China-Plus-One strategy    90

5.2.3.3    Increasing adoption of integrated CDMO service models                 90

5.2.4        CHALLENGES    91

5.2.4.1    Capital-intensive investments for high containment and advanced facilities                 91

5.2.4.2    Quality failures and site shutdowns  91

5.2.4.3    Supply chain concentration risk         91

5.2.4.4    Geopolitical tensions and trade restrictions     92

5.3           TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS            92

5.4           PRICING ANALYSIS          93

5.4.1        INDICATIVE PRICING ANALYSIS, BY KEY PLAYER, 2024                 93

5.4.2        INDICATIVE PRICING ANALYSIS, BY REGION, 2024                 95

5.5           TECHNOLOGY ANALYSIS             96

5.5.1        KEY TECHNOLOGIES     96

5.5.1.1    Continuous manufacturing 96

5.5.1.2    Advanced analytical techniques         97

5.5.1.3    Biocatalysis            97

5.5.2        COMPLEMENTARY TECHNOLOGIES       97

5.5.2.1    Data analytics and digitalization        97

5.5.2.2    Personalized medicines and custom synthesis 97

5.5.2.3    Supercritical fluid technology             98

5.5.3        ADJACENT TECHNOLOGIES       98

5.5.3.1    Supply chain visibility and blockchain               98

5.5.3.2    3D printing            98

5.5.3.3    Nanotechnology    99

5.6           SUPPLY CHAIN ANALYSIS             99

5.7           VALUE CHAIN ANALYSIS               100

5.7.1        RESEARCH & DEVELOPMENT (VALUE ADDITION: 30–35%)       101

5.7.2        CLINICAL TRIALS & REGULATORY APPROVALS (VALUE ADDITION: 50–70%)         102

5.7.3        MANUFACTURING (VALUE ADDITION: 70–80%)                 102

5.7.4        MARKETING & COMMERCIALIZATION (VALUE ADDITION: 80–100%)      102

5.8           ECOSYSTEM ANALYSIS  102

5.9           KEY CONFERENCES & EVENTS   104

5.10         REGULATORY ANALYSIS               105

5.10.1      REGULATORY SCENARIO             106

5.10.1.1  North America      106

5.10.1.1.1                US           106

5.10.1.1.2                Canada   106

5.10.1.2  Europe   106

5.10.1.2.1                Germany                 106

5.10.1.2.2                UK          107

5.10.1.3  Asia Pacific            107

5.10.1.3.1                Japan      107

5.10.1.4  Latin America       107

5.10.1.4.1                Brazil      107

5.10.1.5  Middle East & Africa            107

5.10.1.5.1                Saudi Arabia          107

5.10.2      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             108

5.11         PORTER’S FIVE FORCES ANALYSIS           110

5.11.1      THREAT OF NEW ENTRANTS      112

5.11.2      THREAT OF SUBSTITUTES          112

5.11.3      BARGAINING POWER OF SUPPLIERS       112

5.11.4      BARGAINING POWER OF BUYERS             112

5.11.5      INTENSITY OF COMPETITIVE RIVALRY 112

5.12         KEY STAKEHOLDERS AND BUYING CRITERIA     113

5.12.1      KEY STAKEHOLDERS IN BUYING PROCESS           113

5.12.2      KEY BUYING CRITERIA  114

5.13         CASE STUDY ANALYSIS 115

5.14         MACROECONOMICS INDICATORS           116

5.14.1      HEALTHCARE EXPENDITURE TRENDS  116

5.14.2      GLOBAL CANCER BURDEN          117

5.15         PATENT ANALYSIS          118

5.15.1      LIST OF PATENTS            120

5.16         UNMET NEEDS AND WHITE SPACES       120

5.17         TRADE DATA     121

5.17.1      IMPORT DATA FOR HS CODE–2941           121

5.17.2      EXPORT DATA FOR HS CODE–2941           124

5.18         INVESTMENT AND FUNDING SCENARIO               127

5.19         MANUFACTURING SITES AND CAPACITY EXPANSION OF KEY API SUPPLIERS  128

5.20         IMPACT OF AI/GEN AI ON ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 131

5.20.1      INTRODUCTION              131

5.20.2      IMPACT AND MARKET POTENTIAL OF ARTIFICIAL INTELLIGENCE IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET               131

5.20.3      AI USE CASES     132

5.20.4      FUTURE OF GENERATIVE AI IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET ECOSYSTEM                 133

5.21         IMPACT OF US TARIFF ON ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 134

5.21.1      INTRODUCTION              134

5.21.2      KEY TARIFF RATES          134

5.21.3      PRICE IMPACT ANALYSIS             135

5.21.4      IMPACT ON COUNTRY/REGION                136

5.21.4.1  North America      136

5.21.4.1.1                US           136

5.21.4.2  Europe   136

5.21.4.3  Asia Pacific            136

5.21.5      IMPACT ON END-USE INDUSTRIES          136

5.21.5.1  Pharmaceutical & biotechnology industry        136

5.21.5.2  Contract research organizations (CROs)         137

5.21.5.3  Contract manufacturing organizations (CMOs)             137

6               ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE     138

6.1           INTRODUCTION              139

6.2           ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE (CAPTIVE AND MERCHANT)       139

6.3           INNOVATIVE APIS           140

6.3.1        INCREASING REGULATORY APPROVALS FOR INNOVATIVE DRUGS TO FACILITATE GROWTH                 140

6.4           GENERIC APIS   144

6.4.1        GROWING FOCUS ON GENERIC DRUGS AND LOW MANUFACTURING COSTS TO FUEL MARKET      144

7               ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY            148

7.1           INTRODUCTION              149

7.2           ACTIVE PHARMACEUTICAL INGREDIENTS, BY POTENCY (CAPTIVE AND MERCHANT) 149

7.3           TRADITIONAL APIS        150

7.3.1        INCREASING NUMBER OF APPLICATIONS IN THERAPEUTIC AREAS TO AUGMENT GROWTH 150

7.4           HIGHLY POTENT APIS   154

7.4.1        SYNTHETIC        158

7.4.1.1    Evolving targeted oncology therapies to stimulate growth                 158

7.4.2        BIOLOGICS         161

7.4.2.1    Robust product pipeline to encourage growth 161

8               ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS       165

8.1           INTRODUCTION              166

8.2           ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE OF SYNTHESIS (CAPTIVE AND MERCHANT)                166

8.3           SYNTHETIC APIS              167

8.3.1        INNOVATIVE SYNTHETIC APIS  171

8.3.1.1    High value of innovative APIs to drive market                 171

8.3.2        GENERIC SYNTHETIC APIS          175

8.3.2.1    Increasing need for generic medicines to contribute to growth                 175

8.4           BIOTECH APIS  178

8.4.1        BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE           182

8.4.1.1    Innovative biotech APIs      182

8.4.1.1.1 Growing demand for innovative biopharmaceuticals to drive market    182

8.4.1.2    Generic biotech APIs           186

8.4.1.2.1 Cost-effectiveness and favorable government efforts to fuel market    186

8.4.2        BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT 190

8.4.2.1    Monoclonal antibodies        190

8.4.2.1.1 Growing applications of antibody-drug conjugates in treating cancer to drive market         190

8.4.2.2    Hormones and growth factors            194

8.4.2.2.1 Growing incidence of hormonal disorders to drive market                 194

8.4.2.3    Fusion proteins     197

8.4.2.3.1 Increasing applications of fusion proteins in biopharmaceuticals to aid growth         197

8.4.2.4    Cytokines               200

8.4.2.4.1 Rising use of cytokines in cell signaling, inflammation, and cell growth to spur growth          200

8.4.2.5    Therapeutic enzymes           203

8.4.2.5.1 Growing significance of enzymes in therapies for cancer and pain management to propel market            203

8.4.2.6    Blood factors and anti-coagulants      206

8.4.2.6.1 Growing incidence of hemophilia to fuel market             206

8.4.2.7    Recombinant vaccines         209

8.4.2.7.1 Growing prevalence of infectious diseases to fuel market                 209

8.4.3        BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY EXPRESSION SYSTEM               212

8.4.3.1    Mammalian expression systems         213

8.4.3.1.1 Ability to carry post-translational modifications to drive adoption                 213

8.4.3.2    Microbial expression systems             217

8.4.3.2.1 High expression levels of proteins at low costs to aid growth                 217

8.4.3.3    Yeast expression systems    220

8.4.3.3.1 Efficient protein secretion and simple purification to contribute to growth                220

8.4.3.4    Insect expression systems   224

8.4.3.4.1 Scalability, cost-effectiveness, and favorable safety profile to boost market          224

8.4.3.5    Other expression systems   228

9               ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG 231

9.1           INTRODUCTION              232

9.2           ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE OF DRUG (CAPTIVE AND MERCHANT)          232

9.3           PRESCRIPTION DRUGS 233

9.3.1        INCREASED ADOPTION OF SPECIALTY DRUGS TO SUPPORT GROWTH        233

9.4           OVER-THE-COUNTER DRUGS    237

9.4.1        RISING AWARENESS OF PRECAUTIONARY CARE AND HEALTH

CONCERNS TO SPUR GROWTH 237

10            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION    241

10.1         INTRODUCTION              242

10.2         ACTIVE PHARMACEUTICAL INGREDIENTS, BY THERAPEUTIC APPLICATION

(CAPTIVE AND MERCHANT)       242

10.3         COMMUNICABLE DISEASES        244

10.3.1      INCREASING INVESTMENTS IN DEVELOPING NEW ANTIBIOTICS,

ANTIVIRALS, ANTIFUNGALS, AND VACCINES TO AID GROWTH                 244

10.4         ONCOLOGY        247

10.4.1      GROWING NUMBER OF FDA APPROVALS TO DRIVE MARKET               247

10.5         DIABETES           251

10.5.1      RISING ADVANCEMENTS IN TREATMENT OPTIONS TO EXPEDITE GROWTH       251

10.6         CARDIOVASCULAR DISEASES    255

10.6.1      INCREASING ADOPTION OF GROWTH STRATEGIES BY KEY PLAYERS TO PROMOTE GROWTH  255

10.7         RESPIRATORY DISEASES               258

10.7.1      INCREASING BURDEN OF RESPIRATORY DISORDERS TO BOLSTER GROWTH         258

10.8         PAIN MANAGEMENT      262

10.8.1      RISING DEMAND FOR INNOVATIVE AND ADVANCED PAIN MEDICATIONS TO BOLSTER GROWTH       262

10.9         OTHER THERAPEUTIC APPLICATIONS  265

11            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER            269

11.1         INTRODUCTION              270

11.2         ACTIVE PHARMACEUTICAL INGREDIENTS, BY END USER (CAPTIVE AND MERCHANT)           270

11.3         PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY                 272

11.3.1      RISE IN NEED OF NOVEL TREATMENTS TO EXPEDITE GROWTH             272

11.4         CONTRACT RESEARCH ORGANIZATIONS             275

11.4.1      INCREASING OUTSOURCING OF DRUG R&D ACTIVITIES TO SUPPORT GROWTH 275

11.5         CONTRACT MANUFACTURING ORGANIZATIONS                 279

11.5.1      GROWING FOCUS ON BETTER QUALITY AND REGULATORY

COMPLIANCE TO DRIVE MARKET            279

11.6         OTHER END USERS         282

12            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION                286

12.1         INTRODUCTION              287

12.2         ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION

(CAPTIVE AND MERCHANT)       287

12.3         NORTH AMERICA             289

12.3.1      MACROECONOMIC ANALYSIS OF NORTH AMERICA                 290

12.3.2      US           296

12.3.2.1  High clinical trial & drug discovery activity and efficient regulatory environment to expedite growth     296

12.3.3      CANADA               301

12.3.3.1  Favorable government support and strong product pipeline to sustain growth       301

12.4         EUROPE               306

12.4.1      MACROECONOMIC ANALYSIS OF EUROPE           307

12.4.2      GERMANY           313

12.4.2.1  High healthcare expenditure and advanced R&D facilities to drive market    313

12.4.3      UK          318

12.4.3.1  Rising government investments and growing focus on personalized treatment to fuel market               318

12.4.4      FRANCE                323

12.4.4.1  Increased focus on domestic manufacturing to promote growth                 323

12.4.5      ITALY    328

12.4.5.1  Rising commercial drug development to favor growth   328

12.4.6      SPAIN    333

12.4.6.1  Increase in generic drug manufacturing capacity to propel market                 333

12.4.7      HUNGARY           338

12.4.7.1  Increasing manufacturing activities in pharmaceutical sector to drive market          338

12.4.8      REST OF EUROPE             343

12.5         ASIA PACIFIC     348

12.5.1      MACROECONOMIC ANALYSIS OF ASIA PACIFIC 349

12.5.2      CHINA  355

12.5.2.1  Rise in government policies to increase medicine access and affordability to support growth           355

12.5.3      JAPAN   360

12.5.3.1  Growing geriatric population to boost market 360

12.5.4      INDIA    365

12.5.4.1  Increasing R&D activities and rising government funding initiatives to favor growth   365

12.5.5      SOUTH KOREA  370

12.5.5.1  Rising annual drug exports to drive market     370

12.5.6      AUSTRALIA         375

12.5.6.1  Increasing demand for innovative APIs to propel market                 375

12.5.7      REST OF ASIA PACIFIC   380

12.6         LATIN AMERICA                385

12.6.1      LATIN AMERICA: MACROECONOMIC ANALYSIS 385

12.6.2      BRAZIL 391

12.6.2.1  Increased government investments in pharmaceutical R&D to drive market          391

12.6.3      MEXICO                396

12.6.3.1  Rising investments by foreign firms to support market growth                 396

12.6.4      REST OF LATIN AMERICA             401

12.7         MIDDLE EAST   406

12.7.1      MACROECONOMIC ANALYSIS OF MIDDLE EAST                 406

12.7.2      ISRAEL  412

12.7.2.1  Highly educated workforce and strong culture of innovations to support growth      412

12.7.3      GCC COUNTRIES              417

12.7.3.1  Saudi Arabia          422

12.7.3.1.1                Growing healthcare expenditure to boost market                 422

12.7.3.2  UAE        427

12.7.3.2.1                Rising demand for technologically advanced manufacturing processes to aid growth             427

12.7.3.3  Rest of GCC Countries        432

12.7.4      REST OF MIDDLE EAST 437

12.8         AFRICA 442

12.8.1      GROWING DEMAND FOR PHARMACEUTICAL PRODUCTS TO PROPEL MARKET              442

12.8.2      MACROECONOMIC OUTLOOK FOR AFRICA        442

13            COMPETITIVE LANDSCAPE         449

13.1         INTRODUCTION              449

13.2         OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN

ACTIVE PHARMACEUTICAL INGREDIENTS MARKET        449

13.3         REVENUE ANALYSIS, 2022–2024  451

13.4         MARKET SHARE ANALYSIS, 2024                 452

13.5         COMPANY VALUATION AND FINANCIAL METRICS                 454

13.5.1      YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK

BETA OF KEY VENDORS                455

13.6         BRAND/PRODUCT COMPARISON             456

13.7         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 458

13.7.1      STARS   458

13.7.2      EMERGING LEADERS     458

13.7.3      PERVASIVE PLAYERS      458

13.7.4      PARTICIPANTS 458

13.7.5      COMPETITIVE BENCHMARKING, 2024    460

13.7.5.1  Company footprint               460

13.7.5.2  Region Footprint  461

13.7.5.3  Type footprint       462

13.7.5.4  Potency footprint 463

13.7.5.5  Therapeutic application footprint      464

13.8         COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024        466

13.8.1      PROGRESSIVE COMPANIES         466

13.8.2      RESPONSIVE COMPANIES            466

13.8.3      DYNAMIC COMPANIES  466

13.8.4      STARTING BLOCKS         466

13.8.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024                 468

13.8.5.1  Detailed list of key startups/SMEs    468

13.8.5.2  Competitive benchmarking of key startups/SMEs          470

13.9         COMPETITIVE SCENARIO             471

13.9.1      PRODUCT APPROVALS 471

13.9.2      DEALS  471

13.9.3      EXPANSIONS     473

14            COMPANY PROFILES      476

14.1         KEY PLAYERS     476

14.1.1      PFIZER INC.        476

14.1.1.1  Business overview 476

14.1.1.2  Products offered   477

14.1.1.3  Recent developments           479

14.1.1.3.1                Expansions             479

14.1.1.4  MnM view              480

14.1.1.4.1                Key strengths        480

14.1.1.4.2                Strategic choices   480

14.1.1.4.3                Weaknesses and competitive threats 480

14.1.2      DIVI’S LABORATORIES LIMITED                481

14.1.2.1  Business overview 481

14.1.2.2  Products offered   482

14.1.2.3  Recent developments           483

14.1.2.3.1                Deals      483

14.1.2.3.2                Expansions             484

14.1.2.4  MnM view              484

14.1.2.4.1                Key strengths        484

14.1.2.4.2                Strategic choices   484

14.1.2.4.3                Weaknesses and competitive threats 484

14.1.3      ASYMCHEM INC.               485

14.1.3.1  Business overview 485

14.1.3.2  Products offered   486

14.1.3.3  Recent developments           487

14.1.3.3.1                Deals      487

14.1.3.3.2                Expansions             487

14.1.3.4  MnM view              488

14.1.3.4.1                Key strengths        488

14.1.3.4.2                Strategic choices   488

14.1.3.4.3                Weaknesses and competitive threats 488

14.1.4      CIPLA    489

14.1.4.1  Business overview 489

14.1.4.2  Products offered   490

14.1.4.3  Recent developments           492

14.1.4.3.1                Deals      492

14.1.4.4  MnM view              492

14.1.4.4.1                Key strengths        492

14.1.4.4.2                Strategic choices   493

14.1.4.4.3                Weaknesses and competitive threats 493

14.1.5      EVONIK                494

14.1.5.1  Business overview 494

14.1.5.2  Products offered   495

14.1.5.3  Recent developments           496

14.1.5.3.1                Deals      496

14.1.5.3.2                Expansions             497

14.1.5.4  MnM view              498

14.1.5.4.1                Key strengths        498

14.1.5.4.2                Strategic choices   498

14.1.5.4.3                Weaknesses and competitive threats 498

14.1.6      TEVA PHARMACEUTICAL INDUSTRIES LTD.       499

14.1.6.1  Business overview 499

14.1.6.2  Products offered   500

14.1.6.3  Recent developments           509

14.1.6.3.1                Other developments             509

14.1.7      SANDOZ GROUP AG       510

14.1.7.1  Business overview 510

14.1.7.2  Products offered   511

14.1.7.3  Recent developments           513

14.1.7.3.1                Expansions             513

14.1.8      SK INC. 514

14.1.8.1  Business overview 514

14.1.8.2  Products offered   515

14.1.8.3  Recent developments           516

14.1.8.3.1                Deals      516

14.1.8.3.2                Expansions             516

14.1.9      MERCK KGAA    518

14.1.9.1  Business overview 518

14.1.9.2  Products offered   519

14.1.9.3  Recent developments           520

14.1.9.3.1                Deals      520

14.1.9.3.2                Expansions             521

14.1.10   DR. REDDY’S LABORATORIES LTD.          522

14.1.10.1                 Business overview 522

14.1.10.2                 Products offered   523

14.1.10.3                 Recent developments           525

14.1.10.3.1             Expansions             525

14.1.10.3.2             Other developments             525

14.1.11   SUN PHARMACEUTICAL INDUSTRIES LTD.          526

14.1.11.1                 Business overview 526

14.1.11.2                 Products offered   527

14.1.11.3                 Recent developments           529

14.1.11.3.1             Deals      529

14.1.12   AUROBINDO PHARMA LIMITED                530

14.1.12.1                 Business overview 530

14.1.12.2                 Products offered   531

14.1.12.3                 Recent developments           532

14.1.12.3.1             Deals      532

14.1.13   HIKMA PHARMACEUTICALS PLC               533

14.1.13.1                 Business overview 533

14.1.13.2                 Products offered   534

14.1.13.3                 Recent developments           535

14.1.13.3.1             Deals      535

14.1.13.3.2             Expansions             535

14.1.14   BASF      536

14.1.14.1                 Business overview 536

14.1.14.2                 Products offered   537

14.1.15   ALEMBIC PHARMACEUTICALS LIMITED                539

14.1.15.1                 Business overview 539

14.1.15.2                 Products offered   540

14.1.15.3                 Recent developments           541

14.1.15.3.1             Product launches and approvals         541

14.1.16   SIEGFRIED HOLDING AG              542

14.1.16.1                 Business overview 542

14.1.16.2                 Products offered   543

14.1.16.3                 Recent developments           544

14.1.16.3.1             Deals      544

14.1.16.3.2             Expansions             545

14.1.17   EUROAPI              546

14.1.17.1                 Business overview 546

14.1.17.2                 Products offered   547

14.1.17.3                 Recent developments           547

14.1.17.3.1             Expansions             547

14.1.18   BACHEM              548

14.1.18.1                 Business overview 548

14.1.18.2                 Products offered   549

14.1.19   ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.                 551

14.1.19.1                 Business overview 551

14.1.19.2                 Products offered   551

14.1.20   ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.                 553

14.1.20.1                 Business overview 553

14.1.20.2                 Products offered   553

14.2         OTHER PLAYERS              555

14.2.1      POLYPEPTIDE GROUP   555

14.2.2      GRANULES INDIA            556

14.2.3      CORDEN PHARMA           557

14.2.4      RECIPHARM       558

14.2.5      ABURAIHAN PHARMACEUTICAL COMPANY        559

14.2.6      CURIA GLOBAL, INC.      560

14.2.7      CAMBREX CORPORATION            561

14.2.8      API PHARMA TECH          562

14.2.9      SREEPATHI PHARMACEUTICALS LIMITED           563

14.2.10   SHILPA MEDICARE LIMITED       564

14.2.11   NANJING JIANYOU BIOCHEMICAL PHARMACEUTICAL CO., LTD.             565

14.2.12   HOVIONE            566

14.2.13   CHEMCON GMBH            567

14.2.14   PHARCO PHARMACEUTICALS    567

14.2.15   SAMBI PHARMA PVT. LTD.           568

15            DISCUSSION GUIDE        569

15.1         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                574

15.2         CUSTOMIZATION OPTIONS        576

15.3         RELATED REPORTS         576

15.4         AUTHOR DETAILS           577

LIST OF TABLES

TABLE 1                ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INCLUSIONS AND EXCLUSIONS             50

TABLE 2                IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS  64

TABLE 3                ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: RISK ANALYSIS              67

TABLE 4                PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY REGION,

2023–2030 (USD BILLION)             80

TABLE 5                ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: IMPACT ANALYSIS

OF MARKET DYNAMICS                83

TABLE 6                ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVAL, 2024               87

TABLE 7                EUROPEAN DIRECTORATE FOR QUALITY OF MEDICINES & HEALTHCARE CERTIFICATE OF SUITABILITY TO MONOGRAPHS OF EUROPEAN PHARMACOPOEIA (EDQM CEP) CERTIFICATION ACTIVITY, 2024                88

TABLE 8                INDICATIVE PRICING OF ACTIVE PHARMACEUTICAL INGREDIENTS,

BY KEY PLAYER, 2024 (USD)         94

TABLE 9                INDICATIVE PRICING ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS,

BY REGION, 2024 (USD) 95

TABLE 10              ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: ROLE IN ECOSYSTEM 103

TABLE 11              ACTIVE PHARMACEUTICAL INGREDIENTS: KEY CONFERENCES & EVENTS,

2025–2026              104

TABLE 12              NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 108

TABLE 13              EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  108

TABLE 14              ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  109

TABLE 15              LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  110

TABLE 16              MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  110

TABLE 17              ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: PORTER’S FIVE FORCES             111

TABLE 18              INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%) 113

TABLE 19              BUYING CRITERIA FOR ACTIVE PHARMACEUTICAL INGREDIENTS, BY END USER              114

TABLE 20              ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: CASE STUDY ANALYSIS              115

TABLE 21              HEALTH EXPENDITURE AND FINANCING, 2015–2024 (IN PERCENTAGE OF GDP)                116

TABLE 22              CANCER INCIDENCE, BY REGION, 2022   118

TABLE 23              NUMBER OF PATENTS FILED IN ACTIVE PHARMACEUTICAL

INGREDIENTS MARKET, 2014–2024            119

TABLE 24              ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: LIST OF PATENTS, 2023              120

TABLE 25              IMPORT DATA FOR ANTIBIOTICS HS CODE–2941, 2020-2024, VALUE (USD)     121

TABLE 26              IMPORT DATA FOR ANTIBIOTICS HS CODE–2941, 2020-2024, VOLUME (TONS)              121

TABLE 27              IMPORT DATA FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCL. WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY) HS CODE–2934, 2020-2024,

VALUE (USD)     122

TABLE 28              IMPORT DATA FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCL. WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY) HS CODE–2934, 2020-2024, VOLUME (TONS)         122

TABLE 29              IMPORT DATA FOR HORMONES, PROSTAGLANDINS, THROMBOXANES AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF “INCL. CHAIN MODIFIED POLYPEPTIDES”, USED PRIMARILY AS HORMONES, HS CODE–2937, 2020-2024, VALUE (USD)     123

TABLE 30              IMPORT DATA FOR HORMONES, PROSTAGLANDINS, THROMBOXANES AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF “INCL. CHAIN MODIFIED POLYPEPTIDES”, USED PRIMARILY AS HORMONES, HS CODE–2934, 2020-2024, VOLUME (TONS)              123

TABLE 31              EXPORT DATA FOR ANTIBIOTICS HS CODE–2941, 2020-2024, VALUE (USD)     124

TABLE 32              EXPORT DATA FOR ANTIBIOTICS HS CODE–2941, 2020-2024, VOLUME (TONS)              124

TABLE 33              EXPORT DATA FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCL. WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY) HS CODE–2934,

2020-2024, VALUE (USD)                125

TABLE 34              EXPORT DATA FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCL. WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY) HS CODE–2934, 2020-2024, VOLUME (TONS)         125

TABLE 35              EXPORT DATA FOR HORMONES, PROSTAGLANDINS, THROMBOXANES AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF “INCL. CHAIN MODIFIED POLYPEPTIDES”, USED PRIMARILY AS HORMONE, HS CODE–2934, 2020-2024, VALUE (USD)     126

TABLE 36              EXPORT DATA FOR HORMONES, PROSTAGLANDINS, THROMBOXANES AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF “INCL. CHAIN MODIFIED POLYPEPTIDES”, USED PRIMARILY AS HORMONES, HS CODE–2934, 2020-2024, VOLUME (TONS)              126

TABLE 37              MANUFACTURING SITES OF KEY API SUPPLIERS                 128

TABLE 38              LIST OF SITE EXPANSIONS FOR API MANUFACTURERS, 2023–2025      130

TABLE 39              KEY COMPANIES IMPLEMENTING AI      133

TABLE 40              US ADJUSTED RECIPROCAL TARIFF RATES                 134

TABLE 41              ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             139

TABLE 42              ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE (CAPTIVE AND MERCHANT), 2023–2030 (USD BILLION)             139

TABLE 43              CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             140

TABLE 44              ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE APIS,

BY REGION, 2023–2030 (USD BILLION)    141

TABLE 45              NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2023–2030 (USD BILLION)             141

TABLE 46              EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2023–2030 (USD BILLION)             142

TABLE 47              ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2023–2030 (USD BILLION)             142

TABLE 48              LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2023–2030 (USD BILLION)             143

TABLE 49              MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2023–2030 (USD BILLION)             143

TABLE 50              GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2023–2030 (USD BILLION)             143

TABLE 51              ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC APIS, BY REGION, 2023–2030 (USD BILLION)             144

TABLE 52              NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)        145

TABLE 53              EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC APIS,

BY COUNTRY, 2023–2030 (USD BILLION)                145

TABLE 54              ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)        146

TABLE 55              LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)        146

TABLE 56              MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)        146

TABLE 57              GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)        147

TABLE 58              ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,

2023–2030 (USD BILLION)             149

TABLE 59              ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY

(CAPTIVE AND MERCHANT), 2023–2030 (USD BILLION) 149

TABLE 60              CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,

2023–2030 (USD BILLION)             150

TABLE 61              ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR TRADITIONAL APIS,

BY REGION, 2023–2030 (USD BILLION)    151

TABLE 62              NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2023–2030 (USD BILLION)             151

TABLE 63              EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2023–2030 (USD BILLION)             152

TABLE 64              ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2023–2030 (USD BILLION)             152

TABLE 65              LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2023–2030 (USD BILLION)             153

TABLE 66              MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2023–2030 (USD BILLION)             153

TABLE 67              GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2023–2030 (USD BILLION)             153

TABLE 68              ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS,

BY TYPE, 2023–2030 (USD BILLION)          154

TABLE 69              ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS,

BY REGION, 2023–2030 (USD BILLION)    155

TABLE 70              NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR HIGHLY POTENT APIS, BY COUNTRY, 2023–2030 (USD BILLION)             155

TABLE 71              EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2023–2030 (USD BILLION)      156

TABLE 72              ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2023–2030 (USD BILLION)      156

TABLE 73              LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2023–2030 (USD BILLION)      157

TABLE 74              MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2023–2030 (USD BILLION)      157

TABLE 75              GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2023–2030 (USD BILLION)      157

TABLE 76              ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT SYNTHETIC APIS, BY REGION, 2023–2030 (USD BILLION)             158

TABLE 77              NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)                159

TABLE 78              EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)                159

TABLE 79              ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)                160

TABLE 80              LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)                160

TABLE 81              MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)                160

TABLE 82              GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HIGHLY POTENT SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)                161

TABLE 83              ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD BILLION)                 162

TABLE 84              NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD BILLION)                 162

TABLE 85              EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOLOGICS,

BY COUNTRY, 2023–2030 (USD BILLION)                163

TABLE 86              ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD BILLION)        163

TABLE 87              LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD BILLION)        164

TABLE 88              MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD BILLION)        164

TABLE 89              GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2030 (USD BILLION)        164

TABLE 90              ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS,

2023–2030 (USD BILLION)             166

TABLE 91              ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS (CAPTIVE AND MERCHANT), 2023–2030 (USD BILLION)             166

TABLE 92              CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 (USD BILLION)             167

TABLE 93              SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION,

2023–2030 (USD BILLION)             168

TABLE 94              NORTH AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)             168

TABLE 95              EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY COUNTRY, 2023–2030 (USD BILLION)                169

TABLE 96              ASIA PACIFIC: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY COUNTRY, 2023–2030 (USD BILLION)                169

TABLE 97              LATIN AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY COUNTRY, 2023–2030 (USD BILLION)                170

TABLE 98              MIDDLE EAST: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY COUNTRY, 2023–2030 (USD BILLION)                170

TABLE 99              GCC COUNTRIES: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY COUNTRY, 2023–2030 (USD BILLION)                170

TABLE 100            SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             171

TABLE 101            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE SYNTHETIC APIS, BY REGION, 2023–2030 (USD BILLION)        172

TABLE 102            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)      172

TABLE 103            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)      173

TABLE 104            ASIA PACIFIC: INACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)      173

TABLE 105            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)      174

TABLE 106            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)      174

TABLE 107            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)      174

TABLE 108            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC SYNTHETIC APIS, BY REGION, 2023–2030 (USD BILLION) 175

TABLE 109            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)      176

TABLE 110            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)      176

TABLE 111            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)      177

TABLE 112            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)      177

TABLE 113            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)      178

TABLE 114            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC SYNTHETIC APIS, BY COUNTRY, 2023–2030 (USD BILLION)      178

TABLE 115            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY REGION, 2023–2030 (USD BILLION)             179

TABLE 116            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)        179

TABLE 117            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)        180

TABLE 118            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)        180

TABLE 119            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)        181

TABLE 120            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)        181

TABLE 121            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)        181

TABLE 122            BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             182

TABLE 123            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE BIOTECH APIS, BY REGION, 2023–2030 (USD BILLION)        183

TABLE 124            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)      183

TABLE 125            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)      184

TABLE 126            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)      184

TABLE 127            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)      185

TABLE 128            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)      185

TABLE 129            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INNOVATIVE BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)      185

TABLE 130            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC BIOTECH APIS,

BY REGION, 2023–2030 (USD BILLION)    187

TABLE 131            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)      187

TABLE 132            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)      188

TABLE 133            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)      188

TABLE 134            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)      189

TABLE 135            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)      189

TABLE 136            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR GENERIC BIOTECH APIS, BY COUNTRY, 2023–2030 (USD BILLION)      189

TABLE 137            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY PRODUCT, 2023–2030 (USD BILLION)                190

TABLE 138            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD BILLION)        191

TABLE 139            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)      191

TABLE 140            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)      192

TABLE 141            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)      192

TABLE 142            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)      193

TABLE 143            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)      193

TABLE 144            GCC COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)   193

TABLE 145            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES AND GROWTH FACTORS, BY REGION, 2023–2030 (USD BILLION)             194

TABLE 146            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES AND GROWTH FACTORS, BY COUNTRY, 2023–2030 (USD BILLION)          194

TABLE 147            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET HORMONES AND GROWTH FACTORS, BY COUNTRY, 2023–2030 (USD BILLION)                195

TABLE 148            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES AND GROWTH FACTORS, BY COUNTRY, 2023–2030 (USD BILLION)          195

TABLE 149            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES AND GROWTH FACTORS, BY COUNTRY, 2023–2030 (USD BILLION)          196

TABLE 150            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES AND GROWTH FACTORS, BY COUNTRY, 2023–2030 (USD BILLION)          196

TABLE 151            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES AND GROWTH FACTORS, BY COUNTRY, 2023–2030 (USD BILLION)          196

TABLE 152            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS,

BY REGION, 2023–2030 (USD BILLION)    197

TABLE 153            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)             197

TABLE 154            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)             198

TABLE 155            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)             198

TABLE 156            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)             199

TABLE 157            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)             199

TABLE 158            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)             199

TABLE 159            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY REGION, 2023–2030 (USD BILLION)                 200

TABLE 160            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2023–2030 (USD BILLION)        200

TABLE 161            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES,

BY COUNTRY, 2023–2030 (USD BILLION)                201

TABLE 162            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2023–2030 (USD BILLION)        201

TABLE 163            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2023–2030 (USD BILLION)        202

TABLE 164            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2023–2030 (USD BILLION)        202

TABLE 165            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2023–2030 (USD BILLION)        202

TABLE 166            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY REGION, 2023–2030 (USD BILLION) 203

TABLE 167            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2030 (USD BILLION)      203

TABLE 168            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2030 (USD BILLION)      204

TABLE 169            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR

THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2030 (USD BILLION)             204

TABLE 170            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2030 (USD BILLION)      205

TABLE 171            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2030 (USD BILLION)      205

TABLE 172            GCC COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2023–2030 (USD BILLION)          205

TABLE 173            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS AND ANTI-COAGULANTS, BY REGION, 2023–2030 (USD BILLION)           206

TABLE 174            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS AND ANTI-COAGULANTS, BY COUNTRY, 2023–2030 (USD BILLION)                 206

TABLE 175            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS AND ANTI-COAGULANTS, BY COUNTRY, 2023–2030 (USD BILLION)                 207

TABLE 176            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS AND ANTI-COAGULANTS, BY COUNTRY, 2023–2030 (USD BILLION)                 207

TABLE 177            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS AND ANTI-COAGULANTS, BY COUNTRY, 2023–2030 (USD BILLION)                 208

TABLE 178            MIDDLE EAST: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR BLOOD FACTORS AND ANTI-COAGULANTS, BY COUNTRY,

2023–2030 (USD BILLION)             208

TABLE 179            GCC COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR BLOOD FACTORS AND ANTI-COAGULANTS, BY COUNTRY,

2023–2030 (USD BILLION)             208

TABLE 180            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY REGION, 2023–2030 (USD BILLION) 209

TABLE 181            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)      210

TABLE 182            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)      210

TABLE 183            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)      211

TABLE 184            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)      211

TABLE 185            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)      212

TABLE 186            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)      212

TABLE 187            BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION) 213

TABLE 188            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD BILLION)             214

TABLE 189            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)           214

TABLE 190            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)           215

TABLE 191            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)           215

TABLE 192            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)           216

TABLE 193            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)           216

TABLE 194            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)           216

TABLE 195            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD BILLION)             217

TABLE 196            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)                218

TABLE 197            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)                218

TABLE 198            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)                219

TABLE 199            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)                219

TABLE 200            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)                220

TABLE 201            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)                220

TABLE 202            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD BILLION)        221

TABLE 203            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)      221

TABLE 204            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)      222

TABLE 205            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)      222

TABLE 206            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)      223

TABLE 207            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)      223

TABLE 208            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)      223

TABLE 209            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD BILLION)        225

TABLE 210            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)      225

TABLE 211            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)      226

TABLE 212            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)      226

TABLE 213            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)      227

TABLE 214            MIDDLE EAST: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)                 227

TABLE 215            GCC COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)                 227

TABLE 216            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY REGION, 2023–2030 (USD BILLION)        228

TABLE 217            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR

OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)             228

TABLE 218            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)      229

TABLE 219            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR

OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)             229

TABLE 220            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR

OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)             230

TABLE 221            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR

OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)             230

TABLE 222            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR

OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2023–2030 (USD BILLION)             230

TABLE 223            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG,

2023–2030 (USD BILLION)             232

TABLE 224            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG (CAPTIVE AND MERCHANT), 2023–2030 (USD BILLION)        232

TABLE 225            CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF

DRUG, 2023–2030 (USD BILLION)               233

TABLE 226            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS,

BY REGION, 2023–2030 (USD BILLION)    234

TABLE 227            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2030 (USD BILLION)      234

TABLE 228            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2030 (USD BILLION)      235

TABLE 229            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2030 (USD BILLION)      235

TABLE 230            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2030 (USD BILLION)      236

TABLE 231            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2030 (USD BILLION)      236

TABLE 232            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2023–2030 (USD BILLION)      236

TABLE 233            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-THE-COUNTER DRUGS, BY REGION, 2023–2030 (USD BILLION)        237

TABLE 234            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR

OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2030 (USD BILLION)             238

TABLE 235            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OVER-

THE-COUNTER DRUGS, BY COUNTRY, 2023–2030 (USD BILLION)                 238

TABLE 236            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR

OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2030 (USD BILLION)             239

TABLE 237            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR

OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2030 (USD BILLION)             239

TABLE 238            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR

OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2030 (USD BILLION)             239

TABLE 239            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR

OVER-THE-COUNTER DRUGS, BY COUNTRY, 2023–2030 (USD BILLION)             240

TABLE 240            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)             242

TABLE 241            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION (CAPTIVE AND MERCHANT), 2023–2030 (USD BILLION) 243

TABLE 242            CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)        243

TABLE 243            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY REGION, 2023–2030 (USD BILLION)        244

TABLE 244            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)      245

TABLE 245            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)      245

TABLE 246            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)      246

TABLE 247            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)      246

TABLE 248            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)      247

TABLE 249            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)      247

TABLE 250            LIST OF FDA-APPROVED DRUGS FOR DIFFERENT TYPES OF CANCER 248

TABLE 251            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY,

BY REGION, 2023–2030 (USD BILLION)    248

TABLE 252            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD BILLION)                 249

TABLE 253            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY,

BY COUNTRY, 2023–2030 (USD BILLION)                249

TABLE 254            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD BILLION)                 250

TABLE 255            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD BILLION)                 250

TABLE 256            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD BILLION)                 250

TABLE 257            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD BILLION)                 251

TABLE 258            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES,

BY REGION, 2023–2030 (USD BILLION)    252

TABLE 259            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR DIABETES, BY COUNTRY, 2023–2030 (USD BILLION)                 252

TABLE 260            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES,

BY COUNTRY, 2023–2030 (USD BILLION)                253

TABLE 261            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES,

BY COUNTRY, 2023–2030 (USD BILLION)                253

TABLE 262            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR

DIABETES, BY COUNTRY, 2023–2030 (USD BILLION)         254

TABLE 263            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR

DIABETES, BY COUNTRY, 2023–2030 (USD BILLION)         254

TABLE 264            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD BILLION) 254

TABLE 265            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD BILLION)        255

TABLE 266            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)      256

TABLE 267            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)      256

TABLE 268            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)      257

TABLE 269            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)      257

TABLE 270            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)      257

TABLE 271            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)      258

TABLE 272            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2023–2030 (USD BILLION) 259

TABLE 273            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)      259

TABLE 274            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)      260

TABLE 275            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)      260

TABLE 276            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)      261

TABLE 277            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)      261

TABLE 278            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)      261

TABLE 279            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT,

BY REGION, 2023–2030 (USD BILLION)    262

TABLE 280            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD BILLION)             263

TABLE 281            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD BILLION)             263

TABLE 282            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD BILLION)             264

TABLE 283            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD BILLION)             264

TABLE 284            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD BILLION)             264

TABLE 285            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD BILLION)             265

TABLE 286            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD BILLION)           266

TABLE 287            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD BILLION)                 266

TABLE 288            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD BILLION)                 267

TABLE 289            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD BILLION)                 267

TABLE 290            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD BILLION)                 268

TABLE 291            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD BILLION)                 268

TABLE 292            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR

OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD BILLION) 268

TABLE 293            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER,

2023–2030 (USD BILLION)             270

TABLE 294            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER (CAPTIVE AND MERCHANT), 2023–2030 (USD BILLION) 271

TABLE 295            CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER,

2023–2030 (USD BILLION)             271

TABLE 296            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY REGION, 2023–2030 (USD BILLION)            272

TABLE 297            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY,

2023–2030 (USD BILLION)             273

TABLE 298            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY, 2023–2030 (USD BILLION)             273

TABLE 299            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY,

2023–2030 (USD BILLION)             274

TABLE 300            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY,

2023–2030 (USD BILLION)             274

TABLE 301            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY,

2023–2030 (USD BILLION)             274

TABLE 302            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY,

2023–2030 (USD BILLION)             275

TABLE 303            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2023–2030 (USD BILLION)           276

TABLE 304            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION)                 276

TABLE 305            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION)                 277

TABLE 306            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION)                 277

TABLE 307            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION)                 278

TABLE 308            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION)                 278

TABLE 309            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION)                 278

TABLE 310            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2023–2030 (USD BILLION)    279

TABLE 311            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY,

2023–2030 (USD BILLION)             280

TABLE 312            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION)                 280

TABLE 313            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION)                 281

TABLE 314            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION)                 281

TABLE 315            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD BILLION)                 281

TABLE 316            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY,

2023–2030 (USD BILLION)             282

TABLE 317            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER END USERS,

BY REGION, 2023–2030 (USD BILLION)    283

TABLE 318            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR

OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)                 283

TABLE 319            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR

OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)                 284

TABLE 320            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR

OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)                 284

TABLE 321            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)             285

TABLE 322            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)             285

TABLE 323            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)             285

TABLE 324            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION,

2023–2030 (USD BILLION)             287

TABLE 325            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION

(CAPTIVE AND MERCHANT), 2023–2030 (USD BILLION) 288

TABLE 326            CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION,

2023–2030 (USD BILLION)             288

TABLE 327            NORTH AMERICA: KEY MACROECONOMIC INDICATORS      290

TABLE 328            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY COUNTRY, 2023–2030 (USD BILLION)                291

TABLE 329            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY TYPE, 2023–2030 (USD BILLION)          291

TABLE 330            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY POTENCY, 2023–2030 (USD BILLION) 291

TABLE 331            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)       292

TABLE 332            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             292

TABLE 333            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)                 292

TABLE 334            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 293

TABLE 335            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)                 293

TABLE 336            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)             294

TABLE 337            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY TYPE OF DRUG, 2023–2030 (USD BILLION)     294

TABLE 338            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 295

TABLE 339            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY END USER, 2023–2030 (USD BILLION)                295

TABLE 340            US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             296

TABLE 341            US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,

2023–2030 (USD BILLION)             297

TABLE 342            US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)                 297

TABLE 343            US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)                 297

TABLE 344            US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS,

BY TYPE, 2023–2030 (USD BILLION)          298

TABLE 345            US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY TYPE, 2023–2030 (USD BILLION)          298

TABLE 346            US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY PRODUCT, 2023–2030 (USD BILLION)                299

TABLE 347            US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)          299

TABLE 348            US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG,

2023–2030 (USD BILLION)             300

TABLE 349            US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)             300

TABLE 350            US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER,

2023–2030 (USD BILLION)             301

TABLE 351            CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             302

TABLE 352            CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,

2023–2030 (USD BILLION)             302

TABLE 353            CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 302

TABLE 354            CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             303

TABLE 355            CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)        303

TABLE 356            CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY TYPE, 2023–2030 (USD BILLION)          303

TABLE 357            CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY PRODUCT, 2023–2030 (USD BILLION)                304

TABLE 358            CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)          304

TABLE 359            CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)             305

TABLE 360            CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)        305

TABLE 361            CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER,

2023–2030 (USD BILLION)             306

TABLE 362            EUROPE: KEY MACROECONOMIC INDICATORS                 307

TABLE 363            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY,

2023–2030 (USD BILLION)             308

TABLE 364            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             308

TABLE 365            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,

2023–2030 (USD BILLION)             308

TABLE 366            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 309

TABLE 367            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             309

TABLE 368            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)        309

TABLE 369            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY TYPE, 2023–2030 (USD BILLION)          310

TABLE 370            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY PRODUCT, 2023–2030 (USD BILLION)                310

TABLE 371            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)          311

TABLE 372            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)             311

TABLE 373            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)        312

TABLE 374            EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER,

2023–2030 (USD BILLION)             312

TABLE 375            GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             313

TABLE 376            GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,

2023–2030 (USD BILLION)             314

TABLE 377            GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 314

TABLE 378            GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             314

TABLE 379            GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)        315

TABLE 380            GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 315

TABLE 381            GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)        316

TABLE 382            GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)           316

TABLE 383            GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)             317

TABLE 384            GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)        317

TABLE 385            GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)                 318

TABLE 386            UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             319

TABLE 387            UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,

2023–2030 (USD BILLION)             319

TABLE 388            UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)                 319

TABLE 389            UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)                 320

TABLE 390            UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS,

BY TYPE, 2023–2030 (USD BILLION)          320

TABLE 391            UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY TYPE, 2023–2030 (USD BILLION)          320

TABLE 392            UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY PRODUCT, 2023–2030 (USD BILLION)                321

TABLE 393            UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)          321

TABLE 394            UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG,

2023–2030 (USD BILLION)             322

TABLE 395            UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)             322

TABLE 396            UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER,

2023–2030 (USD BILLION)             323

TABLE 397            FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             324

TABLE 398            FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,

2023–2030 (USD BILLION)             324

TABLE 399            FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 324

TABLE 400            FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             325

TABLE 401            FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)        325

TABLE 402            FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY TYPE, 2023–2030 (USD BILLION)          325

TABLE 403            FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY PRODUCT, 2023–2030 (USD BILLION)                326

TABLE 404            FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)          326

TABLE 405            FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)             327

TABLE 406            FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)        327

TABLE 407            FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER,

2023–2030 (USD BILLION)             328

TABLE 408            ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             328

TABLE 409            ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,

2023–2030 (USD BILLION)             329

TABLE 410            ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 329

TABLE 411            ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             329

TABLE 412            ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS,

BY TYPE, 2023–2030 (USD BILLION)          330

TABLE 413            ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY TYPE, 2023–2030 (USD BILLION)          330

TABLE 414            ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY PRODUCT, 2023–2030 (USD BILLION)                331

TABLE 415            ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)          331

TABLE 416            ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)             332

TABLE 417            ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)        332

TABLE 418            ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER,

2023–2030 (USD BILLION)             333

TABLE 419            SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             334

TABLE 420            SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,

2023–2030 (USD BILLION)             334

TABLE 421            SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 334

TABLE 422            SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             335

TABLE 423            SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS,

BY TYPE, 2023–2030 (USD BILLION)          335

TABLE 424            SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY TYPE, 2023–2030 (USD BILLION)          335

TABLE 425            SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY PRODUCT, 2023–2030 (USD BILLION)                336

TABLE 426            SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)          336

TABLE 427            SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)             337

TABLE 428            SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)        337

TABLE 429            SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER,

2023–2030 (USD BILLION)             338

TABLE 430            HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             339

TABLE 431            HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,

2023–2030 (USD BILLION)             339

TABLE 432            HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)       339

TABLE 433            HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             340

TABLE 434            HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)        340

TABLE 435            HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 340

TABLE 436            HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)        341

TABLE 437            HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)           341

TABLE 438            HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)             342

TABLE 439            HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)        342

TABLE 440            HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)                 343

TABLE 441            REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 344

TABLE 442            REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)                 344

TABLE 443            REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 344

TABLE 444            REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             345

TABLE 445            REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)        345

TABLE 446            REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 345

TABLE 447            REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)        346

TABLE 448            REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)           346

TABLE 449            REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY TYPE OF DRUG, 2023–2030 (USD BILLION)     347

TABLE 450            REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 347

TABLE 451            REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY END USER, 2023–2030 (USD BILLION)                348

TABLE 452            ASIA PACIFIC: KEY MACROECONOMIC INDICATORS      350

TABLE 453            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)                 350

TABLE 454            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             351

TABLE 455            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)                 351

TABLE 456            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 351

TABLE 457            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             352

TABLE 458            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)        352

TABLE 459            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 352

TABLE 460            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)        353

TABLE 461            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)           353

TABLE 462            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)             354

TABLE 463            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)        354

TABLE 464            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)                 355

TABLE 465            CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             356

TABLE 466            CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,

2023–2030 (USD BILLION)             356

TABLE 467            CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 356

TABLE 468            CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             357

TABLE 469            CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS,

BY TYPE, 2023–2030 (USD BILLION)          357

TABLE 470            CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY TYPE, 2023–2030 (USD BILLION)          357

TABLE 471            CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY PRODUCT, 2023–2030 (USD BILLION)                358

TABLE 472            CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)          358

TABLE 473            CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)             359

TABLE 474            CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)        359

TABLE 475            CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER,

2023–2030 (USD BILLION)             360

TABLE 476            JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             361

TABLE 477            JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,

2023–2030 (USD BILLION)             361

TABLE 478            JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 361

TABLE 479            JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             362

TABLE 480            JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS,

BY TYPE, 2023–2030 (USD BILLION)          362

TABLE 481            JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY TYPE, 2023–2030 (USD BILLION)          362

TABLE 482            JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY PRODUCT, 2023–2030 (USD BILLION)                363

TABLE 483            JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)          363

TABLE 484            JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)             364

TABLE 485            JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)        364

TABLE 486            JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER,

2023–2030 (USD BILLION)             365

TABLE 487            INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             366

TABLE 488            INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,

2023–2030 (USD BILLION)             366

TABLE 489            INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 366

TABLE 490            INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             367

TABLE 491            INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS,

BY TYPE, 2023–2030 (USD BILLION)          367

TABLE 492            INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY TYPE, 2023–2030 (USD BILLION)          367

TABLE 493            INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY PRODUCT, 2023–2030 (USD BILLION)                368

TABLE 494            INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)          368

TABLE 495            INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)             369

TABLE 496            INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)        369

TABLE 497            INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER,

2023–2030 (USD BILLION)             370

TABLE 498            SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             371

TABLE 499            SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)                 371

TABLE 500            SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 371

TABLE 501            SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             372

TABLE 502            SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)        372

TABLE 503            SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 372

TABLE 504            SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)        373

TABLE 505            SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)           373

TABLE 506            SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)             374

TABLE 507            SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 374

TABLE 508            SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY END USER, 2023–2030 (USD BILLION)                375

TABLE 509            AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             376

TABLE 510            AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)                 376

TABLE 511            AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 376

TABLE 512            AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             377

TABLE 513            AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)        377

TABLE 514            AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 377

TABLE 515            AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)        378

TABLE 516            AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)           378

TABLE 517            AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)             379

TABLE 518            AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)        379

TABLE 519            AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER, 2023–2030 (USD BILLION)                 380

TABLE 520            REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY TYPE, 2023–2030 (USD BILLION)          381

TABLE 521            REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY POTENCY, 2023–2030 (USD BILLION) 381

TABLE 522            REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)       381

TABLE 523            REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             382

TABLE 524            REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)               382

TABLE 525            REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION)          382

TABLE 526            REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)                383

TABLE 527            REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)          383

TABLE 528            REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY TYPE OF DRUG, 2023–2030 (USD BILLION)     384

TABLE 529            REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 384

TABLE 530            REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY END USER, 2023–2030 (USD BILLION)                385

TABLE 531            LATIN AMERICA: KEY MACRO INDICATORS                 386

TABLE 532            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)                 386

TABLE 533            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 387

TABLE 534            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)                 387

TABLE 535            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 387

TABLE 536            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             388

TABLE 537            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)        388

TABLE 538            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 388

TABLE 539            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)        389

TABLE 540            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)           389

TABLE 541            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)             390

TABLE 542            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 390

TABLE 543            LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY END USER, 2023–2030 (USD BILLION)                391

TABLE 544            BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             392

TABLE 545            BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,

2023–2030 (USD BILLION)             392

TABLE 546            BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 392

TABLE 547            BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             393

TABLE 548            BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)        393

TABLE 549            BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY TYPE, 2023–2030 (USD BILLION)          393

TABLE 550            BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY PRODUCT, 2023–2030 (USD BILLION)                394

TABLE 551            BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)          394

TABLE 552            BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)             395

TABLE 553            BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)        395

TABLE 554            BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER,

2023–2030 (USD BILLION)             396

TABLE 555            MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             397

TABLE 556            MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,

2023–2030 (USD BILLION)             397

TABLE 557            MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 397

TABLE 558            MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             398

TABLE 559            MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)        398

TABLE 560            MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY TYPE, 2023–2030 (USD BILLION)          398

TABLE 561            MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY PRODUCT, 2023–2030 (USD BILLION)                399

TABLE 562            MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)          399

TABLE 563            MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)             400

TABLE 564            MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)        400

TABLE 565            MEXICO: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER,

2023–2030 (USD BILLION)             401

TABLE 566            REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY TYPE, 2023–2030 (USD BILLION)          401

TABLE 567            REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY POTENCY, 2023–2030 (USD BILLION) 402

TABLE 568            REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)       402

TABLE 569            REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             402

TABLE 570            REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)                 403

TABLE 571            REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 403

TABLE 572            REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)                 404

TABLE 573            REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)             404

TABLE 574            REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY TYPE OF DRUG, 2023–2030 (USD BILLION)     405

TABLE 575            REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 405

TABLE 576            REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY END USER, 2023–2030 (USD BILLION)                406

TABLE 577            MIDDLE EAST: KEY MACROECONOMIC INDICATORS      407

TABLE 578            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)                 407

TABLE 579            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             408

TABLE 580            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)                 408

TABLE 581            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 408

TABLE 582            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             409

TABLE 583            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)        409

TABLE 584            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 409

TABLE 585            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)        410

TABLE 586            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)           410

TABLE 587            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)             411

TABLE 588            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)        411

TABLE 589            MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY END USER, 2023–2030 (USD BILLION)                412

TABLE 590            ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             412

TABLE 591            ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,

2023–2030 (USD BILLION)             413

TABLE 592            ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 413

TABLE 593            ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             413

TABLE 594            ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)        414

TABLE 595            ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY TYPE, 2023–2030 (USD BILLION)          414

TABLE 596            ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY PRODUCT, 2023–2030 (USD BILLION)                415

TABLE 597            ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)          415

TABLE 598            ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)             416

TABLE 599            ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)        416

TABLE 600            ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER,

2023–2030 (USD BILLION)             417

TABLE 601            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)                 417

TABLE 602            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2023–2030 (USD BILLION)                 418

TABLE 603            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)                 418

TABLE 604            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 418

TABLE 605            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             419

TABLE 606            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)        419

TABLE 607            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 419

TABLE 608            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)        420

TABLE 609            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)           420

TABLE 610            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY TYPE OF DRUG, 2023–2030 (USD BILLION)     421

TABLE 611            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 421

TABLE 612            GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY END USER, 2023–2030 (USD BILLION)                422

TABLE 613            SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             423

TABLE 614            SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2023–2030 (USD BILLION)                 423

TABLE 615            SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 423

TABLE 616            SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             424

TABLE 617            SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)        424

TABLE 618            SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 424

TABLE 619            SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)                 425

TABLE 620            SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)           425

TABLE 621            SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY TYPE OF DRUG, 2023–2030 (USD BILLION)     426

TABLE 622            SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 426

TABLE 623            SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY END USER, 2023–2030 (USD BILLION)                427

TABLE 624            UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             428

TABLE 625            UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,

2023–2030 (USD BILLION)             428

TABLE 626            UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)                 428

TABLE 627            UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)                 429

TABLE 628            UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS,

BY TYPE, 2023–2030 (USD BILLION)          429

TABLE 629            UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY TYPE, 2023–2030 (USD BILLION)          429

TABLE 630            UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY PRODUCT, 2023–2030 (USD BILLION)                430

TABLE 631            UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)          430

TABLE 632            UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG,

2023–2030 (USD BILLION)             431

TABLE 633            UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)             431

TABLE 634            UAE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER,

2023–2030 (USD BILLION)             432

TABLE 635            REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY TYPE, 2023–2030 (USD BILLION)          433

TABLE 636            REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY POTENCY, 2023–2030 (USD BILLION) 433

TABLE 637            REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)       433

TABLE 638            REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             434

TABLE 639            REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)                 434

TABLE 640            REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 434

TABLE 641            REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)                 435

TABLE 642            REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)             435

TABLE 643            REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY TYPE OF DRUG, 2023–2030 (USD BILLION)     436

TABLE 644            REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 436

TABLE 645            REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY END USER, 2023–2030 (USD BILLION)                437

TABLE 646            REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY TYPE, 2023–2030 (USD BILLION)          438

TABLE 647            REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY POTENCY, 2023–2030 (USD BILLION) 438

TABLE 648            REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION)       438

TABLE 649            REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             439

TABLE 650            REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)                 439

TABLE 651            REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR BIOTECH APIS, BY TYPE, 2023–2030 (USD BILLION) 439

TABLE 652            REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR BIOTECH APIS, BY PRODUCT, 2023–2030 (USD BILLION)                 440

TABLE 653            REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)             440

TABLE 654            REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY TYPE OF DRUG, 2023–2030 (USD BILLION)     441

TABLE 655            REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)                 441

TABLE 656            REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,

BY END USER, 2023–2030 (USD BILLION)                442

TABLE 657            AFRICA: KEY MACROECONOMIC INDICATORS                 443

TABLE 658            AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2023–2030 (USD BILLION)             443

TABLE 659            AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,

2023–2030 (USD BILLION)             444

TABLE 660            AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY HIGHLY POTENT APIS, 2023–2030 (USD BILLION) 444

TABLE 661            AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2023–2030 USD BILLION)             444

TABLE 662            AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR SYNTHETIC APIS, BY TYPE, 2023–2030 (USD BILLION)        445

TABLE 663            AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY TYPE, 2023–2030 (USD BILLION)          445

TABLE 664            AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY PRODUCT, 2023–2030 (USD BILLION)                446

TABLE 665            AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS,

BY EXPRESSION SYSTEM, 2023–2030 (USD BILLION)          446

TABLE 666            AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2023–2030 (USD BILLION)             447

TABLE 667            AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)        447

TABLE 668            AFRICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER,

2023–2030 (USD BILLION)             448

TABLE 669            OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, JANUARY 2022–OCTOBER 2025   450

TABLE 670            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DEGREE OF COMPETITION    453

TABLE 671            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: REGION FOOTPRINT 461

TABLE 672            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: TYPE FOOTPRINT       462

TABLE 673            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: POTENCY FOOTPRINT              463

TABLE 674            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: THERAPEUTIC

APPLICATION FOOTPRINT         464

TABLE 675            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DETAILED LIST

OF KEY STARTUPS/SME PLAYERS             468

TABLE 676            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SME PLAYERS, BY TYPE AND REGION               470

TABLE 677            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: PRODUCT APPROVALS, JANUARY 2022–OCTOBER 2025                 471

TABLE 678            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DEALS,

JANUARY 2022–OCTOBER 2025   471

TABLE 679            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: EXPANSIONS,

JANUARY 2022–OCTOBER 2025   473

TABLE 680            PFIZER INC.: COMPANY OVERVIEW         476

TABLE 681            PFIZER INC.: PRODUCTS OFFERED          477

TABLE 682            PFIZER INC.: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025              479

TABLE 683            DIVI’S LABORATORIES LIMITED: COMPANY OVERVIEW          481

TABLE 684            DIVI’S LABORATORIES LIMITED: PRODUCTS OFFERED             482

TABLE 685            DIVI’S LABORATORIES LIMITED: DEALS, JANUARY 2022–SEPTEMBER 2025                483

TABLE 686            DIVI’S LABORATORIES LIMITED: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025                484

TABLE 687            ASYMCHEM INC.: COMPANY OVERVIEW                 485

TABLE 688            ASYMCHEM INC.: PRODUCTS OFFERED 486

TABLE 689            ASYMCHEM INC.: DEALS, JANUARY 2022–SEPTEMBER 2025              487

TABLE 690            ASYMCHEM INC.: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025              487

TABLE 691            CIPLA: COMPANY OVERVIEW    489

TABLE 692            CIPLA: PRODUCTS OFFERED     490

TABLE 693            CIPLA: DEALS, JANUARY 2022–SEPTEMBER 2025                 492

TABLE 694            EVONIK: COMPANY OVERVIEW 494

TABLE 695            EVONIK: PRODUCTS OFFERED 495

TABLE 696            EVONIK: DEALS, JANUARY 2022–SEPTEMBER 2025        496

TABLE 697            EVONIK: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025              497

TABLE 698            TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW   499

TABLE 699            TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED    500

TABLE 700            TEVA PHARMACEUTICAL INDUSTRIES LTD.: OTHER DEVELOPMENTS,

JANUARY 2022–SEPTEMBER 2025                509

TABLE 701            SANDOZ GROUP AG: COMPANY OVERVIEW                 510

TABLE 702            SANDOZ GROUP AG: PRODUCTS OFFERED                 511

TABLE 703            SANDOZ GROUP AG: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025   513

TABLE 704            SK INC.: COMPANY OVERVIEW  514

TABLE 705            SK INC.: PRODUCTS OFFERED   515

TABLE 706            SK INC.: DEALS, JANUARY 2022–SEPTEMBER 2025                 516

TABLE 707            SK INC.: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025              516

TABLE 708            MERCK KGAA: COMPANY OVERVIEW     518

TABLE 709            MERCK KGAA: PRODUCTS OFFERED      519

TABLE 710            MERCK KGAA: DEALS, JANUARY 2022–SEPTEMBER 2025              520

TABLE 711            MERCK KGAA: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025              521

TABLE 712            DR. REDDY’S LABORATORIES LTD.: COMPANY OVERVIEW          522

TABLE 713            DR. REDDY’S LABORATORIES LTD.: PRODUCTS OFFERED             523

TABLE 714            DR. REDDY’S LABORATORIES LTD.: EXPANSIONS,

JANUARY 2022–SEPTEMBER 2025                525

TABLE 715            DR. REDDY’S LABORATORIES LTD.: OTHER DEVELOPMENTS,

JANUARY 2022–SEPTEMBER 2025                525

TABLE 716            SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW   526

TABLE 717            SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED    527

TABLE 718            SUN PHARMACEUTICAL INDUSTRIES LTD.: DEALS,

JANUARY 2022–SEPTEMBER 2025                529

TABLE 719            AUROBINDO PHARMA LIMITED: COMPANY OVERVIEW          530

TABLE 720            AUROBINDO PHARMA: PRODUCTS OFFERED                 531

TABLE 721            AUROBINDO PHARMA: DEALS, JANUARY 2022–SEPTEMBER 2025              532

TABLE 722            HIKMA PHARMACEUTICALS PLC: COMPANY OVERVIEW          533

TABLE 723            HIKMA PHARMACEUTICALS PLC: PRODUCTS OFFERED             534

TABLE 724            HIKMA PHARMACEUTICALS PLC: DEALS, JANUARY 2022–SEPTEMBER 2025                535

TABLE 725            HIKMA PHARMACEUTICALS PLC: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025                535

TABLE 726            BASF: COMPANY OVERVIEW       536

TABLE 727            BASF: PRODUCTS OFFERED        537

TABLE 728            ALEMBIC PHARMACEUTICALS LIMITED: COMPANY OVERVIEW   539

TABLE 729            ALEMBIC PHARMACEUTICALS LIMITED: PRODUCTS OFFERED    540

TABLE 730            ALEMBIC PHARMACEUTICALS LIMITED: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–SEPTEMBER 2025              541

TABLE 731            SIEGFRIED HOLDING AG: COMPANY OVERVIEW                 542

TABLE 732            SIEGFRIED HOLDING AG: PRODUCTS OFFERED                 543

TABLE 733            SIEGFRIED HOLDING AG: DEALS, JANUARY 2022–SEPTEMBER 2025   544

TABLE 734            SIEGFRIED HOLDING AG: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025                545

TABLE 735            EUROAPI: COMPANY OVERVIEW              546

TABLE 736            EUROAPI: PRODUCTS OFFERED               547

TABLE 737            EUROAPI: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025              547

TABLE 738            BACHEM: COMPANY OVERVIEW               548

TABLE 739            BAYCHEM: PRODUCTS OFFERED             549

TABLE 740            ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW       551

TABLE 741            ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.: PRODUCTS OFFERED        551

TABLE 742            ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW   553

TABLE 743            ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.: PRODUCTS OFFERED    553

TABLE 744            POLYPEPTIDE GROUP: COMPANY OVERVIEW                 555

TABLE 745            GRANULES INDIA: COMPANY OVERVIEW                 556

TABLE 746            CORDEN PHARMA: COMPANY OVERVIEW                 557

TABLE 747            RECIPHARMA: COMPANY OVERVIEW     558

TABLE 748            ABURAIHAN PHARMACEUTICAL COMPANY: COMPANY OVERVIEW   559

TABLE 749            CURIA GLOBAL, INC.: COMPANY OVERVIEW                 560

TABLE 750            CAMBREX CORPORATION: COMPANY OVERVIEW          561

TABLE 751            API PHARMA TECH: COMPANY OVERVIEW                 562

TABLE 752            SREEPATHI PHARMACEUTICALS LIMITED: COMPANY OVERVIEW   563

TABLE 753            SHILPA MEDICARE LIMITED: COMPANY OVERVIEW          564

TABLE 754            NANJING JIANYOU BIOCHEMICAL PHARMACEUTICAL CO., LTD.:

COMPANY OVERVIEW   565

TABLE 755            HOVIONE: COMPANY OVERVIEW             566

TABLE 756            CHEMCON GMBH: COMPANY OVERVIEW                 567

TABLE 757            PHARCO PHARMACEUTICALS: COMPANY OVERVIEW          567

TABLE 758            SAMBI PHARMA PVT. LTD.: COMPANY OVERVIEW          568

LIST OF FIGURES

FIGURE 1              ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION

& REGIONAL SCOPE       51

FIGURE 2              ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: YEARS CONSIDERED  52

FIGURE 3              ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: RESEARCH DESIGN     54

FIGURE 4              ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: KEY DATA FROM

SECONDARY SOURCES  56

FIGURE 5              ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: BREAKDOWN OF

PRIMARY INTERVIEWS  57

FIGURE 6              ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE ESTIMATION

(SUPPLY-SIDE ANALYSIS), 2024  58

FIGURE 7              COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH, 2024      59

FIGURE 8              REVENUE SHARE ANALYSIS OF PFIZER, INC., 2024        59

FIGURE 9              ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE VALIDATION FROM PRIMARY SOURCES   61

FIGURE 10            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: TOP-DOWN APPROACH            62

FIGURE 11            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: CAGR PROJECTIONS  63

FIGURE 12            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DATA TRIANGULATION            65

FIGURE 13            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE,

2025 VS. 2030 (USD BILLION)       70

FIGURE 14            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY,

2025 VS. 2030 (USD BILLION)       70

FIGURE 15            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS,

2025 VS. 2030 (USD BILLION)       71

FIGURE 16            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG,

2025 VS. 2030 (USD BILLION)       71

FIGURE 17            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2025 VS. 2030 (USD BILLION)             72

FIGURE 18            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY END USER,

2025 VS. 2030 (USD BILLION)       73

FIGURE 19            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2025–2030                 74

FIGURE 20            INCREASING DRUG R&D PIPELINE AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET                 76

FIGURE 21            INNOVATIVE APIS AND US TO LEAD NORTH AMERICAN MARKET IN 2025        77

FIGURE 22            SYNTHETIC SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD       77

FIGURE 23            MONOCLONAL ANTIBODIES SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD                78

FIGURE 24            CHINA TO LEAD MARKET DURING FORECAST PERIOD                78

FIGURE 25            EMERGING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD  79

FIGURE 26            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    82

FIGURE 27            GLOBAL PHARMACEUTICAL R&D SPENDING, 2023–2030, (USD BILLION)            86

FIGURE 28            NEW REVENUE POCKETS FOR PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET        93

FIGURE 29            INDICATIVE PRICING ANALYSIS OF API, BY TYPE, 2024           95

FIGURE 30            INDICATIVE PRICING ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS,

BY REGION, 2024               96

FIGURE 31            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: SUPPLY CHAIN ANALYSIS         99

FIGURE 32            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: VALUE CHAIN ANALYSIS           101

FIGURE 33            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: ECOSYSTEM ANALYSIS              102

FIGURE 34            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET:

PORTER’S FIVE FORCES ANALYSIS           111

FIGURE 35            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE          113

FIGURE 36            KEY BUYING CRITERIA FOR END USERS                 114

FIGURE 37            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: PATENT ANALYSIS,

JANUARY 2014–DECEMBER 2024 119

FIGURE 38            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: INVESTMENT

AND FUNDING SCENARIO, 2025 (USD MILLION)                127

FIGURE 39            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: AI USE CASES 132

FIGURE 40            NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT         289

FIGURE 41            ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT         349

FIGURE 42            REVENUE SHARE ANALYSIS OF KEY PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2022–2024 (USD MILLION) 451

FIGURE 43            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE ANALYSIS OF

KEY PLAYERS, 2024           453

FIGURE 44            EV/EBITDA OF KEY VENDORS   455

FIGURE 45            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: BRAND/PRODUCT COMPARISON         457

FIGURE 46            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024                 459

FIGURE 47            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY FOOTPRINT             460

FIGURE 48            ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024        467

FIGURE 49            PFIZER INC.: COMPANY SNAPSHOT (2024)                 477

FIGURE 50            DIVI’S LABORATORIES LIMITED: COMPANY SNAPSHOT (2024)             481

FIGURE 51            ASYMCHEM INC.: COMPANY SNAPSHOT (2024)                 486

FIGURE 52            CIPLA: COMPANY SNAPSHOT (2024)        490

FIGURE 53            EVONIK: COMPANY SNAPSHOT (2024)   495

FIGURE 54            TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024)      500

FIGURE 55            SANDOZ GROUP AG: COMPANY SNAPSHOT (2024)    511

FIGURE 56            SK INC.: COMPANY SNAPSHOT (2024)     515

FIGURE 57            MERCK KGAA: COMPANY SNAPSHOT (2024)                 519

FIGURE 58            DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2024)             523

FIGURE 59            SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024)      527

FIGURE 60            AUROBINDO PHARMA LIMITED: COMPANY SNAPSHOT (2024)             531

FIGURE 61            HIKMA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2024)             534

FIGURE 62            BASF: COMPANY SNAPSHOT (2024)          537

FIGURE 63            ALEMBIC PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2024)      540

FIGURE 64            SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2024)    543

FIGURE 65            EUROAPI: COMPANY SNAPSHOT (2024) 546

FIGURE 66            BAYCHEM: COMPANY SNAPSHOT (2024)                 549

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧